122 related articles for article (PubMed ID: 10184937)
1. Pharmacoeconomics perspectives: payers, providers, and patients.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S221-4. PubMed ID: 10184937
[No Abstract] [Full Text] [Related]
2. Primary prevention.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S185-90. PubMed ID: 10184933
[No Abstract] [Full Text] [Related]
3. Clinical and economic considerations of coronary heart disease: a managed care approach. Proceedings based on presentations from two conferences, Cardiovascular Event Reduction: Defining the Role of HMG Therapy in Managed Care, held November 14-16, 1997 in Philadelphia, and Pharmacoeconomics & Outcomes Issues of Lipid Therapy, held November 5-7, 1997 in Orlando.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S168-233. PubMed ID: 10180343
[No Abstract] [Full Text] [Related]
4. Forecasting cholesterol management--end of the statin gold rush?
Crownover BK; Curtiss FR
J Manag Care Pharm; 2006; 12(6):479-85. PubMed ID: 16925456
[TBL] [Abstract][Full Text] [Related]
5. The economics of lipid management.
Mullins CD
Manag Care; 2001 Nov; 10(11 Suppl):17-8; discussion 19-24. PubMed ID: 11761626
[No Abstract] [Full Text] [Related]
6. Methods and mindsets in pharmacoeconomics.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S213-5. PubMed ID: 10184935
[No Abstract] [Full Text] [Related]
7. Secondary prevention.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S201-8. PubMed ID: 10184934
[No Abstract] [Full Text] [Related]
8. Assessing the value and affordability of cholesterol reduction in the managed care setting.
Gonzalez ER; Kannewurf BS
Am J Manag Care; 1998 Apr; 4(4 Suppl):S226-33; quiz S234-5. PubMed ID: 10180344
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe.
Perkerson KA; Gillespie EL; Coleman CI
Conn Med; 2005 Jan; 69(1):19-22. PubMed ID: 15736370
[No Abstract] [Full Text] [Related]
10. Employers push to manage prescription drug costs.
Frieden J
Bus Health; 1992 May; 10(6):43-6, 48, 50. PubMed ID: 10119119
[No Abstract] [Full Text] [Related]
11. Issues and controversies in pharmacoeconomics.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S216-20. PubMed ID: 10184936
[No Abstract] [Full Text] [Related]
12. Economic benefits of aggressive lipid lowering: a managed care perspective.
McKenney JM; Kinosian B
Am J Manag Care; 1998 Jan; 4(1):65-74. PubMed ID: 10179907
[TBL] [Abstract][Full Text] [Related]
13. Specialty pharmacy management adjusts to new financial realities.
Reinke T
Manag Care; 2013 Apr; 22(4):13-4. PubMed ID: 23678558
[No Abstract] [Full Text] [Related]
14. Pharmaceutical formularies: the right formula for cost and utilization?
Austin B
Find Brief; 2004 Aug; 7(5):1-3. PubMed ID: 15298009
[No Abstract] [Full Text] [Related]
15. A new frontier for prescription drug services.
Frankel RB
J Health Care Benefits; 1994; 3(6):24-30. PubMed ID: 10135306
[TBL] [Abstract][Full Text] [Related]
16. Controlling the cost of branded drugs.
Mandelker J
Bus Health; 1993 Nov; 11(13):44-6, 48. PubMed ID: 10130506
[TBL] [Abstract][Full Text] [Related]
17. Shifting gears.
Tweed V
Bus Health; 1994 May; 12(5):28-9, 32, 34 passim. PubMed ID: 10134334
[No Abstract] [Full Text] [Related]
18. Need for integrated data in pharmacy benefits.
Martens G; Clor GE
J Health Care Benefits; 1993; 3(1):57-60. PubMed ID: 10130352
[No Abstract] [Full Text] [Related]
19. Reduced mortality rates after intensive statin therapy in managed-care patients.
Fintel D; Joyce A; Mackell J; Graff J; Kuntze E; Ollendorf DA
Value Health; 2007; 10(2):161-9. PubMed ID: 17391425
[TBL] [Abstract][Full Text] [Related]
20. Precipitating factors for pharmaceutical firms.
McCarthy R
State Health Care Am; 1997; ():39-43. PubMed ID: 10168083
[No Abstract] [Full Text] [Related]
[Next] [New Search]
